Measles and rubella virus vaccine - Beijing Minhai BiotechnologyAlternative Names: Lyophilised live attenuated measles and rubella combined vaccine - Beijing Minhai Biotechnology; MR attenuated combined vaccine - Beijing Minhai Biotechnology
Latest Information Update: 25 Aug 2015
At a glance
- Originator Beijing Minhai Biotechnology
- Class Measles vaccines; Rubella vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Measles; Rubella